儿童CAR-T细胞治疗的挑战与展望

doi:10.12372/jcp.2024.24e0578

Abstract

Abstract:

It has been more than 10 years since chimeric antigen receptor T cells (CAR-T) therapy were first used to treat children with relapsed acute lymphoblastic leukemia, and thousands of patients worldwide have benefited from it. CAR-T treatment has greatly improved the overall prognosis of relapsed and refractory pediatric acute lymphoblastic leukemia patients and is gradually changing the treatment history of relapsed and refractory pediatric hematological tumor patients. Currently, CAR-T treatment for children still faces some challenges, but overall, the prospects are extremely promising.

Key words: chimeric antigen receptor T cell, challenge, prospect, child

LI Benshang, YANG Liu. Challenges and prospects of CAR-T treatment for pediatric disease[J].Journal of Clinical Pediatrics, 2024, 42(7): 573-577.

References 40

[1]	Daei Sorkhabi A, Mohamed Khosroshahi L, Sarkesh A, et al. The current landscape of CAR T-cell therapy for solid tumors: mechanisms, research progress, challenges, and counterstrategies[J]. Front Immunol, 2023, 14: 1113882.
[2]	Pui CH, Yang JJ, Hunger SP, et al. Childhood acute lymphoblastic leukemia: progress through collaboration[J]. J Clin Oncol, 2015, 33(27): 2938-2948.
[3]	Gupta A, Cripe TP. Immunotherapies for pediatric solid tumors: a targeted update[J]. Paediatr Drugs, 2022, 24(1): 1-12.
[4]	Wang F, Fu K, Wang Y, et al. Small-molecule agents for cancer immunotherapy[J]. Acta Pharm Sin B, 2024, 14(3): 905-952. doi: 10.1016/j.apsb.2023.12.010 pmid: 38486980
[5]	Cuesta-Mateos C, Alcaraz-Serna A, Somovilla-Crespo B, et al. Monoclonal antibody therapies for hematological malignancies: not just lineage-specific targets[J]. Front Immunol, 2017, 8: 1936. doi: 10.3389/fimmu.2017.01936 pmid: 29387053
[6]	Cappell KM, Kochenderfer JN. Long-term outcomes following CAR T cell therapy: what we know so far[J]. Nat Rev Clin Oncol, 2023, 20(6): 359-371. doi: 10.1038/s41571-023-00754-1 pmid: 37055515
[7]	Talleur AC, Qudeimat A, Métais JY, et al. Preferential expansion of CD8+ CD19-CAR T cells postinfusion and the role of disease burden on outcome in pediatric B-ALL[J]. Blood Adv, 2022, 6(21): 5737-5749.
[8]	Zhu M, Wu B, Brandl C, et al. Blinatumomab, a bispecific T-cell engager (BiTE®) for CD19^- targeted cancer immunotherapy: clinical pharmacology and its implications[J]. Clin Pharmacokinet, 2016, 55(10): 1271-1288.
[9]	Wang T, Tang Y, Cai J, et al. Coadministration of CD19- and CD22-directed chimeric antigen receptor T-Cell therapy in childhood B-cell acute lymphoblastic leukemia: a single-arm, multicenter, phase Ⅱ trial[J]. J Clin Oncol, 2023, 41(9): 1670-1683.
[10]	Xiao X, Huang S, Chen S, et al. Mechanisms of cytokine release syndrome and neurotoxicity of CAR T-cell therapy and associated prevention and management strategies[J]. J Exp Clin Cancer Res, 2021, 40(1): 367. doi: 10.1186/s13046-021-02148-6 pmid: 34794490
[11]	Siegler EL, Kenderian SS. Neurotoxicity and cytokine release syndrome after chimeric antigen receptor T cell therapy: insights into mechanisms and novel therapies[J]. Front Immunol, 2020, 11: 1973. doi: 10.3389/fimmu.2020.01973 pmid: 32983132
[12]	Hines MR, Knight TE, McNerney KO, et al. Immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome[J]. Transplant Cell Ther, 2023, 29(7): 438.
[13]	Wat J, Barmettler S. Hypogammaglobulinemia after chimeric antigen receptor CAR T-cell therapy: characteristics, management, and future directions[J]. J Allergy Clin Immunol Pract, 2022, 10(2): 460-466.
[14]	Jain MD, Smith M, Shah NN. How I treat refractory CRS and ICANS after CAR T-cell therapy[J]. Blood, 2023, 141(20): 2430-2442.
[15]	Zhang Y, Zhou F, Wu Z, et al. Timing of tocilizumab administration under the guidance of IL-6 in CAR-T therapy for R/R acute lymphoblastic leukemia[J]. Front Immunol, 2022, 13:914959.
[16]	Rainone M, Ngo D, Baird JH, et al. Interferon-γ blockade in CAR T-cell therapy-associated macrophage activation syndrome/hemophagocytic lymphohistiocytosis[J]. Blood Adv, 2023, 7(4): 533-536.
[17]	Manni S, Del Bufalo F, Merli P, et al. Neutralizing IFNγ improves safety without compromising efficacy of CAR-T cell therapy in B-cell malignancies[J]. Nat Commun, 2023, 14(1): 3423. doi: 10.1038/s41467-023-38723-y pmid: 37296093
[18]	Xu N, Yang XF, Xue SL, et al. Ruxolitinib reduces severe CRS response by suspending CAR-T cell function instead of damaging CAR-T cells[J]. Biochem Biophys Res Commun, 2022, 595: 54-61.
[19]	Mestermann K, Giavridis T, Weber J, et al. The tyrosine kinase inhibitor dasatinib acts as a pharmacologic on/off switch for CAR T cells[J]. Sci Transl Med, 2019, 11(499): eaau5907.
[20]	Ventin M, Cattaneo G, Maggs L, et al. Implications of high tumor burden on chimeric antigen receptor T-Cell immunotherapy: a review[J]. JAMA Oncol, 2024, 10(1): 115-121.
[21]	Sterner RC, Sterner RM. Immune effector cell associated neurotoxicity syndrome in chimeric antigen receptor-T cell therapy[J]. Front Immunol, 2022, 13:879608.
[22]	Gu T, Hu K, Si X, et al. Mechanisms of immune effector cell-associated neurotoxicity syndrome after CAR-T treatment[J]. WIREs Mech Dis, 2022, 14(6): e1576.
[23]	Sheth VS, Gauthier J. Taming the beast: CRS and ICANS after CAR T-cell therapy for ALL[J]. Bone Marrow Transplant, 2021, 56(3): 552-566.
[24]	Gatto L, Ricciotti I, Tosoni A, et al. CAR-T cells neurotoxicity from consolidated practice in hematological malignancies to fledgling experience in CNS tumors: fill the gap[J]. Front Oncol, 2023, 13: 1206983.
[25]	Nix MA, Mandal K, Geng H, et al. Surface proteomics reveals CD72 as a target for in vitro-evolved nanobody-based CAR-T cells in KMT2A/MLL1-rearranged B-ALL[J]. Cancer Discov, 2021, 11(8): 2032-2049. doi: 10.1158/2159-8290.CD-20-0242 pmid: 33727310
[26]	Leung KT, Cai J, Liu Y, et al. Prognostic implications of CD9 in childhood acute lymphoblastic leukemia: insights from a nationwide multicenter study in China[J]. Leukemia, 2024, 38(2): 250-257. doi: 10.1038/s41375-023-02089-3 pmid: 38001171
[27]	Zhao Z, Sadelain M. CAR T cell design: approaching the elusive AND-gate[J]. Cell Res, 2023, 33(10): 739-740. doi: 10.1038/s41422-023-00828-w pmid: 37221269
[28]	Coorens THH, Collord G, Treger TD, et al. Clonal origin of KMT2A wild-type lineage-switch leukemia following CAR-T cell and blinatumomab therapy[J]. Nature Cancer, 2023, 4(8): 1095-1101.
[29]	Gu R, Liu W, Mei Y, et al. The impact of ZNF384 rearranged on antigen editing during treatment-specific selective pressures in adult B cell acute lymphoid leukemia[J]. Blood, 2023, 142: 4209.
[30]	De Bie J, Demeyer S, Gielen O, et al. BCR-ABL1 positive B-ALL can undergo T-cell lineage shift to become CD19 negative T-ALL[J]. HemaSphere, 2018, 2(3): e42.
[31]	Liang M, Gong D, Wang L, et al. PAX5 haploinsufficiency induced CD8+ T cells dysfunction or exhaustion by high expression of immune inhibitory-related molecules[J]. Cancer Treat Res Commun, 2021, 28: 100437.
[32]	Majzner RG, Ramakrishna S, Yeom KW, et al. GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas[J]. Nature, 2022, 603(7903): 934-941.
[33]	Bufalo FD, Angelis BD, Caruana I, et al. GD2-CART01 for relapsed or refractory high-risk neuroblastoma[J]. N Engl J Med, 2023, 388(14): 1284-1295.
[34]	Maalej KM, Merhi M, Inchakalody VP, et al. CAR-cell therapy in the era of solid tumor treatment: current challenges and emerging therapeutic advances[J]. Mol Cancer, 2023, 22(1): 20. doi: 10.1186/s12943-023-01723-z pmid: 36717905
[35]	Ayala Ceja M, Khericha M, Harris CM, et al. CAR-T cell manufacturing: major process parameters and next-generation strategies[J]. J Exp Med, 2024, 221(2): e20230903.
[36]	Yang J, He J, Zhang X, et al. Next-day manufacture of a novel anti-CD19 CAR-T therapy for B-cell acute lymphoblastic leukemia: first-in-human clinical study[J]. Blood Cancer J, 2022, 12(7): 104. doi: 10.1038/s41408-022-00694-6 pmid: 35798714
[37]	Lin H, Cheng J, Mu W, et al. Advances in universal CAR-T cell therapy[J]. Front Immunol, 2021, 12:744823.
[38]	Jo S, Das S, Williams A, et al. Endowing universal CAR T-cell with immune-evasive properties using TALEN-gene editing[J]. Nat Commun, 2022, 13(1): 3453. doi: 10.1038/s41467-022-30896-2 pmid: 35773273
[39]	Muller F, Taubmann J, Bucci L, et al. CD19 CAR T-cell therapy in autoimmune disease - a case series with follow-up[J]. N Engl J Med, 2024, 390(8): 687-700.
[40]	Schett G, Mackensen A, Mougiakakos D. CAR T-cell therapy in autoimmune diseases[J]. Lancet, 2023, 402(10416): 2034-2044. doi: 10.1016/S0140-6736(23)01126-1 pmid: 37748491

Challenges and prospects of CAR-T treatment for pediatric disease

RichHTML

PDF (PC)

Like

Knowledge

Abstract

Cite this article

share this article

References 40

Related Articles 15

Metrics

Comments

Recommended 0

[1]	LUO Mingjing, YU Jiaming, WANG Xiaodong, ZHANG Xiaoling, YU Yue, ZHANG Yu, WEN Feiqiu, LIU Sixi. Clinical analysis of invasive fungal disease secondary to allogeneic hematopoietic stem cell transplantation in 424 children with thalassemia [J]. Journal of Clinical Pediatrics, 2025, 43(1): 21-28.
[2]	LIU Dongxia, JIN Rong, LIN Rongjun. Risk factors analysis of severe refractory Mycoplasma pneumoniae pneumonia complicated with bronchitis obliterans in children [J]. Journal of Clinical Pediatrics, 2025, 43(1): 29-34.
[3]	ZHONG Jinhong, WANG Can, CHEN Fang. Progress in the research of infantile fiberoptic bronchoscopy sedation [J]. Journal of Clinical Pediatrics, 2025, 43(1): 50-55.
[4]	JIANG Weiqin, WANG Jing, CHENG Anna, CHEN Tingting, HUANG Yujuan. Predictors of recurrent febrile seizures during the same febrile illness in children with febrile seizures [J]. Journal of Clinical Pediatrics, 2025, 43(1): 8-13.
[5]	QIU Xiu, WEI Dongmei, LIN Shanshan, XIA Huimin, ZHOU Wenhao. Principles and practice of the Born in Guangzhou Cohort Study [J]. Journal of Clinical Pediatrics, 2024, 42(9): 747-752.
[6]	FAN Jianxia. The origins and development of the healthy life trajectory program: a cohort of community-family-mother-child multidimensional interventions for overweight and obesity in children [J]. Journal of Clinical Pediatrics, 2024, 42(9): 768-773.
[7]	JIANG Tao, LI Shuangjie, TANG Lian, OUYANG Wenxian. Immunobiological properties of peripheral blood MAIT cells in children with chronic hepatitis B [J]. Journal of Clinical Pediatrics, 2024, 42(9): 787-790.
[8]	ZHOU Jie, LIU Keqiang, WANG Jinling, WANG Ying. Megacystis-microcolon-intestinal hypoperistalsis syndrome caused by MYH11 elongating mutation : a case report and literatures review [J]. Journal of Clinical Pediatrics, 2024, 42(9): 798-804.
[9]	CHU Sijia, TANG Jihong. Research progress of central nervous system injury associated with pediatric acute lymphoblastic leukemia and its treatment [J]. Journal of Clinical Pediatrics, 2024, 42(9): 811-816.
[10]	DING Yaping, XIA Shanshan, ZHANG Chenmei. Interpretation of “2023 Children’s Renal Nutrition Working Group Clinical Practice Recommendations: Nutritional Management of Children with Acute Kidney Injury” [J]. Journal of Clinical Pediatrics, 2024, 42(8): 667-672.
[11]	LI Yirong, LI Huiping, GAO Jingyu, XIAO Yuhua, CHEN Xiaomin, LU Yanling, ZHAO Nana, FENG Xiaoqin. Comparison of different doses of cytarabine for induction chemotherapy in children with acute myeloid leukemia in FLAG-IDA regimen [J]. Journal of Clinical Pediatrics, 2024, 42(8): 673-677.
[12]	HUANG Bo, DONG Yanying, SONG Linlan. Clinical characteristics of 348 children with infectious mononucleosis [J]. Journal of Clinical Pediatrics, 2024, 42(8): 678-683.
[13]	WANG Dan, SHAO Jingbo, LI Hong, ZHANG Na, ZHU Jiashi, FU Pan, WANG Zhen. Clinical analysis of 38 cases of hematological malignancies complicated with tumor lysis syndrome in children [J]. Journal of Clinical Pediatrics, 2024, 42(8): 684-690.
[14]	MA Yan, WEI Xingjiao, BAI Hua, ZHANG Yan, TIAN Xinmin, Aqsa Ahmad, LIANG Lijun. Analysis of etiological composition and clinical features of stage 5 chronic kidney disease in children in a tertiary hospital in western China [J]. Journal of Clinical Pediatrics, 2024, 42(8): 697-703.
[15]	WANG Ye, ZHANG Linlin, CHI Zuofei, SUN Ruowen, JIANG Zehui, XU Gang. A case of clinical report of T-lymphoblastic lymphoma secondary to acute promyelocytic leukemia in children [J]. Journal of Clinical Pediatrics, 2024, 42(8): 722-727.